PVCT Statistics
Total Valuation
Provectus Biopharmaceuticals has a market cap or net worth of 50.91 million. The enterprise value is 53.53 million.
| Market Cap | 50.91M |
| Enterprise Value | 53.53M |
Important Dates
The last earnings date was Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Provectus Biopharmaceuticals has 420.28 million shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 420.28M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 8.00% |
| Owned by Institutions (%) | 0.07% |
| Float | 386.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 70.22 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -17.68 |
| EV / Sales | 73.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.12
| Current Ratio | 0.12 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.23 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -108.92% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 180,980 |
| Profits Per Employee | -757,164 |
| Employee Count | 4 |
| Asset Turnover | 0.58 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.31% in the last 52 weeks. The beta is 0.59, so Provectus Biopharmaceuticals's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -24.31% |
| 50-Day Moving Average | 0.11 |
| 200-Day Moving Average | 0.14 |
| Relative Strength Index (RSI) | 60.84 |
| Average Volume (20 Days) | 285,753 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.00 |
Income Statement
In the last 12 months, Provectus Biopharmaceuticals had revenue of 723,918 and -3.03 million in losses. Loss per share was -0.01.
| Revenue | 723,918 |
| Gross Profit | -1.09M |
| Operating Income | -2.17M |
| Pretax Income | -3.03M |
| Net Income | -3.03M |
| EBITDA | -2.16M |
| EBIT | -2.17M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 187,457 in cash and 2.80 million in debt, giving a net cash position of -2.61 million or -0.01 per share.
| Cash & Cash Equivalents | 187,457 |
| Total Debt | 2.80M |
| Net Cash | -2.61M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -5.42M |
| Book Value Per Share | -0.01 |
| Working Capital | -5.46M |
Cash Flow
| Operating Cash Flow | -2.93M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -150.69% |
| Operating Margin | -299.98% |
| Pretax Margin | -418.37% |
| Profit Margin | n/a |
| EBITDA Margin | -298.75% |
| EBIT Margin | -299.98% |
| FCF Margin | n/a |
Dividends & Yields
Provectus Biopharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.03% |
| Shareholder Yield | -0.03% |
| Earnings Yield | -5.96% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Provectus Biopharmaceuticals has an Altman Z-Score of -456.08. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -456.08 |
| Piotroski F-Score | n/a |